Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's Wegovy.

The move could open the door to China securing more advanced computing power from the U.S. even as the two countries battled for technology supremacy, critics said.